**PlasmaMATCH Publications Bibliography (last updated 31/01/2024)**

(From plasmaMATCH publications endnote library saved here: [\\CTRIALS\CTRIALS\SHARED\TRIALDOCS\plasmaMATCH\Presentations, Publications, Publicity\Publications List\plasmaMATCH Publications.enl](file:///\\CTRIALS\CTRIALS\SHARED\TRIALDOCS\plasmaMATCH\Presentations,%20Publications,%20Publicity\Publications%20List\plasmaMATCH%20Publications.enl))

1. Bliss J, Kernaghan S, Fribbens C, Stevenson L, Morden J, Snowdon C, Macpherson I, Wardley A, Roylance R, Baird R. The UK plasma based molecular profiling of advanced breast cancer to inform therapeutic choices (plasmamatch) trial: a multiple parallel cohort, open-label, multi-centre phase IIa clinical trial aiming to provide proof of principle efficacy for designated targeted therapies in patients with advanced breast cancer where the targetable mutation is identified through ctDNA screening (CRUK/15/010). Trials. 2017;18(1):200.

<https://doi.org/10.1186/s13063-017-1902-y>

2. Turner N, Bye H, Kernaghan S, Prozsek P, Fribbens C, Moretti L, Morden J, Snowdon C, Macpherson I, Wardley A, Roylance R, Baird R, Bliss J, Ring A. The plasmaMATCH Trial: A multiple parallel cohort, open-label, multi-centre phase-II clinical trial of ctDNA

screening to direct targeted therapies in patients with advanced breast cancer (CRUK/15/010). Breast Cancer Research and Treatment. 2018;167(1):309-405.

<https://doi.org/10.1007/s10549-017-4585-x>

3. Turner N, Bye H, Kernaghan S, Proszek P, Fribbens C, Moretti L, Morden J, Snowdon C, Macpherson I, Wardley A, Roylance R, Baird R, Bliss J, Ring A. Abstract OT1-06-03: The plasmaMATCH trial: A multiple parallel cohort, open-label, multi-centre phase II clinical trial of ctDNA screening to direct targeted therapies in patients with advanced breast cancer (CRUK/15/010). Cancer Research. 2018;78(4\_Supplement):OT1-06-3.

<https://doi.org/10.1158/1538-7445.SABCS17-OT1-06-03>

4. Kernaghan S, Moretti L, Kilburn L, Wilkinson K, Snowdon C, Morden J, Macpherson I, Wardley A, Roylance R, Baird R, Ring A, Turner N, Bliss J, , on behalf of the plasmaMATCH Trial Management Group. The UK plasma based Molecular profiling of Advanced breast cancer to inform Therapeutic CHoices (plasmaMATCH) Trial: A multiple parallel-cohort, phase IIa platform trial aiming to provide proof of principle efficacy for designated targeted therapies in patient subgroups identified through ctDNA screening (CRUK/15/010). Trials. 2019;20:579.

<https://doi.org/10.1186/s13063-019-3688-6>

5. Snowdon C, Kernaghan S, Moretti L, Wilkinson K, Martin S, Elwood G, Fynn S, J B. Operational challenges of running platform trials – ICR-CTSU experience based on the plasmaMATCH trial Trials. 2019;20(1):579.

<https://doi.org/10.1186/s13063-019-3688-6>

6. Kernaghan S SC, Moretti L, Wilkinson K, Martin S, Elwood G, Fynn S, Bliss J Patient and Public Involvement in the Delivery of Platform Trials – ICR-CTSU experience. Trials. 2019;20(1):579.

<https://doi.org/10.1186/s13063-019-3688-6>

7. Baird RD, Kilburn L, Kernaghan S, Wardley AM, Macpherson I, Roylance R, Stephens P, Oikonomidou O, Braybrooke JP, Tuthill M, Abraham J, Winter MC, Kingston B, Wilkinson K, Turner N, Ring A, Bliss JM, on behalf of the plasma MTMG. Abstract P1-19-14: Results from plasmaMATCH trial treatment cohort D: A phase II trial of capivasertib in patients with an AKT activation basket mutation identified via ctDNA testing or tumour sequencing (CRUK/15/010). Cancer Research. 2020;80(4\_Supplement):P1-19-4.

<https://doi.org/10.1158/1538-7445.SABCS19-P1-19-14>

8. Macpherson I, Kilburn L, Kernaghan S, Wardley AM, Baird RD, Roylance R, Stephens P, Oikonomidou O, Braybrooke JP, Tuthill M, Abraham J, Winter MC, Kingston B, Wilkinson K, Ring A, Bliss JM, Turner N, on behalf of the plasma MTMG. Abstract P1-19-04: Results from plasmaMATCH trial treatment cohort A: A phase II trial of extended-dose fulvestrant in patients with an ESR1 mutation identified via ctDNA screening (CRUK/15/010). Cancer Research. 2020;80(4\_Supplement):P1-19-04-P1-19-04.

<https://doi.org/10.1158/1538-7445.SABCS19-P1-19-04>

9. Wardley AM, Kilburn L, Kernaghan S, Macpherson I, Baird RD, Roylance R, Stephens P, Oikonomidou O, Braybrooke JP, Tuthill M, Abraham J, Winter MC, Kingston B, Wilkinson K, Bliss JM, Ring A, Turner N, on behalf of the plasma MTMG. Abstract P1-19-07: Results from plasmaMATCH trial treatment cohort B: A phase II trial of neratinib plus fulvestrant in ER positive breast cancer or neratinib alone in ER negative breast cancer in patients with a HER2 mutation identified via ctDNA screening (CRUK/15/010). Cancer Research. 2020;80(4\_Supplement):P1-19-07-P1-19-07.

<https://doi.org/10.1158/1538-7445.SABCS19-P1-19-07>

10. Roylance R, Kilburn L, Kernaghan S, Wardley AM, Macpherson I, Baird RD, Stephens P, Oikonomidou O, Braybrooke JP, Tuthill M, Abraham J, Winter MC, Kingston B, Wilkinson K, Ring A, Bliss JM, Turner N, on behalf of the plasma MTMG. Abstract P1-19-11: Results from plasmaMATCH trial treatment cohort C: A phase II trial of capivasertib plus fulvestrant in ER positive breast cancer patients with an AKT1 mutation identified via ctDNA screening (CRUK/15/010). Cancer Research. 2020;80(4\_Supplement):P1-19-1-P1--1.

<https://doi.org/10.1158/1538-7445.SABCS19-P1-19-11>

11. Turner N, Kingston B, Kilburn L, Kernaghan S, Wardley AM, Macpherson I, Baird RD, Roylance R, Stephens P, Oikonomidou O, Braybrooke JP, Tuthill M, Abraham J, Winter MC, Bye H, Hubank M, Snowdon C, Rea D, Cameron D, Shaaban A, Randle K, Wilkinson K, Moretti L, Bliss JM, Ring A, on behalf of the plasma MTMG. Abstract GS3-06: Results from the plasmaMATCH trial: A multiple parallel cohort, multi-centre clinical trial of circulating tumour DNA testing to direct targeted therapies in patients with advanced breast cancer (CRUK/15/010). Cancer Research. 2020;80(4\_Supplement):GS3-06-GS3-.

<https://doi.org/10.1158/1538-7445.SABCS19-GS3-06>

12. Kingston B, Bye H, Hubank M, Walsh G, Swift C, Beaney M, Kilburn L, Kernaghan S, Wardley AM, Macpherson I, Baird RD, Roylance R, Wilkinson K, Garcia-Murillas I, Bliss JM, Turner N, Ring A, on behalf of the plasma MTMG. Abstract GS3-07: The genomic landscape of breast cancer based on ctDNA analysis: Data from the plasmaMATCH trial. Cancer Research. 2020;80(4\_Supplement):GS3-07-GS3-.

<https://doi.org/10.1158/1538-7445.SABCS19-GS3-07>

13. Turner NC, Kingston B, Kilburn LS, Kernaghan S, Wardley AM, Macpherson IR, Baird RD, Roylance R, Stephens P, Oikonomidou O, Braybrooke JP, Tuthill M, Abraham J, Winter MC, Bye H, Hubank M, Gevensleben H, Cutts R, Snowdon C, Rea D, Cameron D, Shaaban A, Randle K, Martin S, Wilkinson K, Moretti L, Bliss JM, Ring A. Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial. The Lancet Oncology. 2020;21(10):1296-308.

<https://doi.org/10.1016/S1470-2045(20)30444-7>

14. Pascual J, Cutts RJ, Kingston B, Hrebien S, Kilburn LS, Kernaghan S, Moretti L, Wilkinson K, Wardley AM, Macpherson IR, Baird RD, Roylance R, Hubank M, Walsh G, Faull I, Banks KC, Lanman RB, Garcia-Murillas I, Bliss JM, Ring A, Turner NC. Abstract PS5-02: Assessment of early ctDNA dynamics to predict efficacy of targeted therapies in metastatic breast cancer: Results from plasmaMATCH trial. Cancer Research. 2021;81(4\_Supplement):PS5-02-PS5-.

<https://doi.org/10.1158/1538-7445.SABCS20-PS5-02>

15. Kingston B, Cutts RJ, Bye H, Beaney M, Walsh-Crestani G, Hrebien S, Swift C, Kilburn LS, Kernaghan S, Moretti L, Wilkinson K, Wardley AM, Macpherson IR, Baird RD, Roylance R, Reis-Filho JS, Hubank M, Faull I, Banks KC, Lanman RB, Garcia-Murillas I, Bliss JM, Ring A, Turner NC. Genomic profile of advanced breast cancer in circulating tumour DNA. Nature Communications. 2021;12(1):2423.

<https://doi.org/10.1038/s41467-021-22605-2>

16. Kingston B, Cutts R, Beaney M, Walsh-Crestani G, Hrebien S, Kilburn L, Kernaghan S, Moretti L, Wilkinson K, MacPherson I, Baird RD, Roylance R, Reis-Filho JS, Hubank M, Faull I, Banks K, Garcia-Murillas I, Bliss J, Ring A, Turner N. 99P Analysis of ctDNA in advanced breast cancer reveals polyclonal disease associated with adverse outcome. Annals of Oncology. 2021;32:S65-S6.

<https://doi.org/10.1016/j.annonc.2021.03.214>

17. Snowdon C, Kernaghan S, Moretti L, Turner NC, Ring A, Wilkinson K, Martin S, Foster S, Kilburn LS, Bliss JM. Operational complexity versus design efficiency: challenges of implementing a phase IIa multiple parallel cohort targeted treatment platform trial in advanced breast cancer. Trials. 2022;23(1):372.

<https://doi.org/10.1186/s13063-022-06312-x>

18. Ring AE, Moretti L, Afshari-Mehr A, Wardley AM, Kilburn L, Gurel B, MacPherson IR, Baird RD, Martin S, Pearson A, Roylance R, Winter M, Dunne K, Copson E, Hickish T, Stephens P, Burcombe RJ, Randle K, Bliss J, Turner NC. Results from plasmaMATCH trial cohort E: A phase II trial of olaparib and ceralasertib in patients with triple-negative advanced breast cancer (CRUK/15/010). Journal of Clinical Oncology. 2022;40(16\_suppl):1024-.

<https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.1024>

19. Kingston B, Pearson A, Herrera-Abreu MT, Cutts R, Moretti L, Kilburn L, Johnson H, MacPherson IR, Ring AE, Bliss J, Katzenellenbogen JA, Turner NC. ESR1 F404 mutations and acquired resistance to fulvestrant in the plasmaMATCH study. Journal of Clinical Oncology. 2022;40(16\_suppl):1009-.

<https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.1009>

20. Ring A, Kilburn LS, Pearson A, Moretti L, Afshari-Mehr A, Wardley AM, Gurel B, Macpherson IR, Riisnaes R, Baird RD, Martin S, Roylance R, Johnson H, Ferreira A, Winter MC, Dunne K, Copson E, Hickish T, Burcombe R, Randle K, Serra V, Llop-Guevara A, Bliss JM, Turner NC. Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010). Clinical Cancer Research. 2023;29(23):4751-9.

<https://doi.org/10.1158/1078-0432.CCR-23-1696>

21. Kingston B, Pearson A, Herrera-Abreu MT, Sim L-X, Cutts RJ, Shah H, Moretti L, Kilburn LS, Johnson H, Macpherson IR, Ring A, Bliss JM, Hou Y, Toy W, Katzenellenbogen JA, Chandarlapaty S, Turner NC. ESR1 F404 Mutations and Acquired Resistance to Fulvestrant in ESR1-Mutant Breast Cancer. Cancer Discovery. 2024:OF1-OF16.

<https://doi.org/10.1158/2159-8290.CD-22-1387>

22. Iseult M. Browne, Javier Pascual, Rosalind J Cutts, Belinda Kingston, Sarah Hrebien, Lucy S. Kilburn, Alex Pearson, Laura Moretti, Andrew M. Wardley, Iain R. Macpherson, Richard D. Baird, Rebecca Roylance, Iris Faull, Kimberly C. Banks, Richard B. Lanman, Isaac Garcia-Murillas, Judith M. Bliss, Alistair Ring and Nicholas C. Turner.

**The prognostic and predictive impact of circulating tumour DNA (ctDNA) dynamics in patients with metastatic Triple Negative Breast Cancer (TNBC) on olaparib based therapy: Results from Cohort E of the PlasmaMATCH trial**

**Presentation at SABCS 2023 Abstract should be available in cancer research 2024 (around feb 15th) to add to end note library when available.**